21 September 2018 in Baylor University Medical Center Proceedings
We report the first case of atopic dermatitis successfully treated with the oral Janus kinase-1 (JAK1) inhibitor oclacitinib. A man in his 70s, with a 6-year history of skin disease refractory to topical and biologic therapies, self-prescribed this veterinary medication with rapid remission of symptoms. He has remained in remission for 7 months with no reported adverse side effects or infections. JAK1 plays a central role in expression of proinflammatory cytokines IL-4, IL-5, and IL-13, which play an important role in the pathogenesis of atopic dermatitis. Ruxolitinib and tofacitinib are JAK inhibitors currently approved by the Food and Drug Administration for the treatment of myelofibrosis, rheumatoid arthritis, and psoriatic arthritis in humans. Oclacitinib is not currently indicated for use in humans.
9 May 2018 in Baylor University Medical Center Proceedings
We report the first case of a 34-year-old woman with histiocytoid Sweet syndrome (HSS) that was successfully treated with etanercept. HSS is a rare histological variant of acute febrile neutrophilic dermatosis that was described by Requena et al in 2005. It is distinguished by dermal infiltration by mononuclear cells with a histiocytic morphology. To date there are three reported cases of the use of etanercept in the treatment of classic febrile neutrophilic dermatosis but none targeting this disease variant. Our patient presented with a 6-month history of scattered erythematous papules on the neck, trunk, and upper and lower limbs bilaterally. Clinical findings and histopathological evaluation were highly suggestive of HSS. After 32 months of refractory disease activity, our patient was initiated on a regimen of etanercept 1 mg/kg subcutaneously twice weekly and topical desoximetasone 0.05% ointment twice daily as required. To date, our patient has achieved 37 months of remission.
17 May 2019 in Baylor University Medical Center Proceedings
We report the first case of an 82-year-old woman with five basal cell carcinomas within a large nevus sebaceous of the trunk. Nevus sebaceous of Jadassohn is a congenital cutaneous hamartoma affecting 0.3% of newborns. Clinical diagnosis is based on its distinctive hairless, orange-brown appearance. Up to 51% of nevus sebaceous may exhibit secondary neoplasia, and basal cell carcinoma is thought to occur in approximately 1% of lesions. Our patient presented with an asymptomatic, pigmented verrucous plaque on the upper right back that had been present since birth. Histopathology of concerning papules within the nevus sebaceous were consistent with five basal cell carcinomas and two follicular adnexal neoplasms. The patient was treated with local excisions, topical imiquimod, and close monitoring.
7 August 2019 in The American Journal of Tropical Medicine and Hygiene
"Extensive, Multifocal Cutaneous Leishmaniasis Presenting with Varied Morphologies in an Immunosuppressed Patient" published on 07 Aug 2019 by The American Society of Tropical Medicine and Hygiene.
2 January 2019 in Baylor University Medical Center Proceedings
We present the case of a 55-year-old black man with coccidiomycosis presenting as a cutaneous plaque on the upper lip. Coccidiomycosis, or “valley fever,” is caused by the virulent, dimorphic, soil-dwelling fungus Coccidiodes immitis. Seen in up to 50% of symptomatic patients, skin involvement by coccidiomycosis can present as papules, pustules, plaques, nodules, abscesses, or ulcerations. Diagnosis of coccidiomycosis relies on serology and identification in clinical specimens, and first-line treatment includes fluconazole, ketoconazole, or itraconazole. Recognizing the cutaneous manifestations of this mycotic infection is essential for diagnosis in otherwise asymptomatic patients.
17 May 2019 in Baylor University Medical Center Proceedings
(2019). A medical student perspective on solutions for burnout. Baylor University Medical Center Proceedings. Ahead of Print.